Gothenburg, September 13, 2021 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immunooncological treatments focusing on CAR T-cells and oncolytic viruses, announced today that ESGCT (European Society of Gene & Cell Therapy) and PEGS Europe (Protein & Antibody Engineering Summit) has selected the company's submitted abstracts entitled “Expression of a pathogenic virulence factor enhances the efficacy of CAR T-cell therapy against solid tumors” for oral presentations.
Elicera's Chief Development Officer, Dr Di Yu, will orally present preclinical proof-of-concept data for the company's iTANK platform during the upcoming ESGCT Collaborative Virtual Congress to be held on October 19-22, 2021. This is also the first time the iTANK platform will be publicly presented. Elicera's Chief Scientific Officer, professor Magnus Essand, will then present corresponding data and additional preclinical data on the company's CAR T-cell therapy for the treatment of B-cell lymphoma at PEGS Europe on November 2-4, 2021.
"The iTANK platform has been developed to improve the function of CAR T cells but also to activate a separate attack by the immune system against the entire set of relevant targets on cancer cells via the patient's own so-called killer T-cells," says CEO Jamal El-Mosleh. “We use the technology to strengthen our own drug candidates, including next generation of oncolytic viruses, which is why it is considered one of our most important assets. The platform however can be applied to all CAR T-cells under development and since they can meet two of the biggest challenges for CAR T-cells in the treatment of solid tumors, the area with the greatest potential, we see the platform itself as a very important business opportunity. That is why we are particularly looking forward to presenting the iTANK platform to various stakeholders publicly for the first time”.
For further information please contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB
Phone: +46 (0) 703 31 90 51
About the iTANK platform
The iTANK (immunoTherapies Activated with NAP for efficient Killing) platform is the company's own fully developed technology platform for strengthening and arming CAR T-cells. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating protein (NAP) from the bacterium Helicobacter pylori. Upon activation, NAP has been shown to be able to enhance the function of the CAR T-cell in addition to activating a parallel immune response via CD8 + killer T-cells. It is expected to be able to generate a broad attack against most targets on cancer cells. The iTANK platform is used to strengthen the company's own CAR T cells but can also be applied to other CAR T-cells under development.
About Elicera Therapeutics AB
Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses. In addition, Elicera has developed a technology platform called iTANK that can be used to optimize all CAR T cells in development and activate killer T cells against cancer. The Company’s share (ELIC) is traded on Nasdaq First North Growth Market. G&W Fondkommission has been appointed the Company's Certified Adviser. E-mail: firstname.lastname@example.org, tel: +468-503 000 50.
For more information, please visit www.elicera.com